CACrown ArchivesThe cinema collection
Menu
Research dossier · General Reference

COVAX

global vaccine alliance regarding the COVID-19 pandemic

Cross-disciplinary reference desk with index cards, atlas, dictionary and catalogue
General referenceInterpretive dossier study · Crown Archives visual atlas
Record originEnglish Wikipedia
Text licenseCC BY-SA 4.0
Source revisionAug 2, 2026
Entity authorityQ99360983
Source-derived summary

COVID-19 Vaccines Global Access, abbreviated as COVAX, was a worldwide initiative aimed at equitable access to COVID-19 vaccines directed by the GAVI vaccine alliance, the Coalition for Epidemic Preparedness Innovations (CEPI), and the World Health Organization (WHO), alongside key delivery partner UNICEF. It was one of the four pillars of the Access to COVID-19 Tools Accelerator, an initiative begun in April 2020 by the WHO, the European Commission, and the government of France as a response to the COVID-19 pandemic. COVAX coordinated international resources to enable low-to-middle-income countries equitable access to COVID-19 tests, therapies, and vaccines. UNICEF was the key delivery partner, leveraging its experience as the largest single vaccine buyer in the world and working on the procurement of COVID-19 vaccine doses, as well as logistics, country readiness and in-country delivery.

By 19 October 2020, 184 countries had joined COVAX.

COVAX began distributing vaccines in February 2021. Though COVAX promised 100 million doses by the end of March, this goal was not reached until 6 July. By mid-August 2021, COVAX delivered 200 million vaccine doses to nearly 140 countries instead of the 600 million doses initially projected. The continued shortage of COVID-19 vaccines delivered through COVAX is blamed on "vaccine nationalism" by richer nations, and the diversion of 400 million Oxford–AstraZeneca COVID-19 vaccine doses, produced under license by the Serum Institute of India (SII), for domestic use in India. As of April 2022, more than 1.4 billion doses were delivered, when the largest recipients were Bangladesh (183 million doses), Pakistan (112 million) and Indonesia (104 million).

History

In April 2020 the World Health Organization (WHO), the European Commission, and the government of France founded the Access to COVID-19 Tools Accelerator, an initiative begun as a response to the COVID-19 pandemic. COVID-19 Vaccines Global Access (COVAX) is one of its four pillars.

Editorial summary

Begin with the source’s own compact description: “COVAX” is global vaccine alliance regarding the COVID-19 pandemic. The dossier treats that line as a proposition to test through COVAX, global and vaccine, not as a finished interpretation.

Editorial reviewA concise reference frame for defining the subject, testing terminology and identifying the institution closest to the evidence. The current lead gives the account dated anchors—2020, 2021, 2022—that can be checked directly. The linked authority record independently contributes the date 2020. For this dossier, COVAX, global and vaccine is the immediate research focus.
Editorial analysis

Why this record matters

The phrase “global vaccine alliance regarding the COVID-19 pandemic” supplies a clear boundary for inquiry. It also exposes the unanswered questions: who defined that boundary, when it became stable and which sources sit outside it.

Evidence profile

Vocabulary and entity names are the principal evidence signals here, because they determine the precision of every later search. The source revision retrieved here is dated Aug 2, 2026. The linked authority identifier is Q99360983. None of the 4 selected statements returned an explicit reference. The first chronological checks are 2020, 2021 and 2022.

Critical limits

The absence of detail may reflect summary conventions rather than a lack of surviving documentation. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.

How to read it

Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.

Best used for
  • Subject orientation
  • Search vocabulary
  • Locating named sources
Verify next

The closest primary source, responsible institution and strongest cited specialist reference.

Three-step research path

  1. Establish the record: confirm the title “COVAX”, its source revision and the description used here.
  2. Expand the search: follow COVAX primary sources, COVAX archive and COVAX research across catalogues and specialist indexes.
  3. Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.

Questions for further research

  1. Which source most directly establishes the central claim about “COVAX”?
  2. What terminology or title could unlock a more precise catalogue search?
  3. Which cited source is closest to the event, object or claim?
Subject index

Search terms from this dossier

Source & attribution

This entry incorporates text from COVAX” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.